ArticleOPEN ACCESS

HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma

HemaSphere
DOI: 10.1097/HS9.0000000000000325
4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Stevens, W. B. C., Bakunina, K., Cuijpers, M., Chamuleau, M., Beeker, A., Fijnheer, R., … Kersten, M. J. (2020). HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma. HemaSphere. Wolters Kluwer Health. https://doi.org/10.1097/HS9.0000000000000325

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free